Mr. Truex is the CEO and Chairman of Thryv Therapeutics (previously LQT Therapeutics). Over the course of two decades he has been involved in over $5 billion of life science financings and strategic transactions. His recent experience includes initial public offerings for Milestone (Board Member 2019), Trius (Board Member 2010), Anthera (CEO 2010), Peninsula (CEO 2004), and Versicor (Vice President 2000).

Prior to Thryv, Mr. Truex founded Anthera Pharmaceuticals, a publicly traded biotech company with large clinical programs in cardiovascular disease, lupus, inflammation and cystic fibrosis. Mr. Truex was Founder, President and CEO of Peninsula Pharmaceuticals, an antibiotic development company that was acquired by Johnson and Johnson and Forest for more than $700 million. Mr. Truex began his life science career at Eli Lilly and Company where his business development experience included the Lilly ICOS joint venture for the development of Cialis® and several successful out-licensing programs. He obtained his MBA from Indiana University and a BA in Economics from the University of Waterloo. Mr. Truex currently serves on the Board of Directors for Find Therapeutics and Feldan. He is an Acting Board Member of the Indiana University Johnson Center for Entrepreneurship and Innovation. He is a former member of the Board of Directors for Milestone (MIST), Anthera (ANTH), Trius (TSRX), CymaBay (CBAY), Eiger (EIGR), Protagonist (PTGX), and Peninsula Pharmaceuticals.

• 

  Chief Executive Officer (CEO) in Thryv Therapeutics

  We will relentlessly pursue precision treatments targeting SGK1 to enable people to live their absolute best lives.Without Limits.

• 

  Chairman of the Board in Thryv Therapeutics

  We will relentlessly pursue precision treatments targeting SGK1 to enable people to live their absolute best lives.Without Limits.